INTRODUCTION {#s1}
============

In 2007, the fat mass and obesity associated (*FTO*) gene was reported as the first obesity related gene by the genome-wide association studies (GWAS) in Caucasian population \[[@R1], [@R2]\]. Subsequently, the following studies confirmed the positive associations between single nucleotide polymorphisms (SNPs) in/near *FTO* gene and obesity risk in diverse populations \[[@R3]--[@R5]\].

*FTO* gene was found to affect the function of the central nervous system, as well as adipose tissue at a peripheral level. As obesity is a well established risk factor for most types of cancer, it is interesting and important to investigate whether *FTO* SNPs are associated with risk of cancer. Up to now, a total of 27 publications have examined the associations between *FTO* SNPs and risk of cancer \[[@R6]--[@R32]\]. However, the results have been inconsistent. Three meta-analyses have summarized the associations between *FTO* SNPs and risk of cancer \[[@R33]--[@R35]\]; however, there are several limitations for them. First, they did not address whether the associations were mediated through body mass index (BMI)/obesity. Second, many eligible studies were omitted. Third, two of three from the same study team examined the association between each of two SNPs (rs8050136\[[@R34]\] and rs9939609\[[@R35]\]) in/near *FTO* gene and cancer risk. It is illogical to do the separate analyses for these two SNPs as they are in strong linkage disequilibrium (LD, *r*^2^\>0.90) in both European and Asian populations.

Therefore, we aimed to perform an updated meta-analysis to investigate the associations between *FTO* rs9939609 SNP (or any proxy SNP, *r*^2^\>0.90) and other SNPs which are not in tight LD with rs9939609 SNP (such as rs1477196 and rs11075995) and cancer risk. In addition, we also aimed to examine whether the associations are independent of adiposity.

RESULTS {#s2}
=======

Characteristics of the studies {#s2_1}
------------------------------

A flow chart describing the process of inclusion/exclusion of studies is presented in Figure [1](#F1){ref-type="fig"}. The literature search identified a total of 238 potentially relevant articles. At last, a total of 27 publications (129,467 cancer cases and 290,633 normal controls) were included in our meta-analysis. There were 24 publications (113780 cases and 210593 controls) for *FTO* rs9939609 SNP, 5 publications (1594 cases and 2034 controls) for *FTO* rs1477196 SNP, and 3 publications (14144 cases and 79973 controls) for rs11075995 variant. All three SNPs in the each of included studies were in Hardy-Weinberg Equivalent. The characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}.

![Flowchart for inclusion/exclusion of studies](oncotarget-08-50987-g001){#F1}

###### The detailed characteristics of the included studies in the meta-analysis

  Study \*                         Country                                                                                   Ethnicity     Type ofcancer                No. of cases   No. of controls   OR      95% CI   SNP     Adjustmentfor BMI   
  -------------------------------- ----------------------------------------------------------------------------------------- ------------- ---------------------------- -------------- ----------------- ------- -------- ------- ------------------- -----
  Brennan, 2009 \[[@R6]\]          Czech Republic, Hungary, Poland, Romania, Russia, and Slovakia                            European      Lung cancer                  2250           3052              0.92    0.84     1.00    rs9939609           No
  Brennan, 2009 \[[@R6]\]          Czech Republic, Hungary, Poland, Romania, Russia, and Slovakia                            European      Kidney cancer                954            3052              1.06    0.95     1.19    rs9939609           No
  Brennan, 2009 \[[@R6]\]          Czech Republic, Hungary, Poland, Romania, Russia, and Slovakia                            European      Upper aerodigestive cancer   811            3052              0.98    0.87     1.12    rs9939609           No
  Gaudet, 2010 \[[@R7]\]           USA and Australia                                                                         Mixed         Endometrial cancer           417            406               1.05    0.86     1.28    rs8050136           No
  Lewis, 2010 \[[@R8]\]            UK                                                                                        European      Prostate cancer              1550           1815              0.94    0.85     1.03    rs9939609           Yes
  Meyer, 2010 \[[@R9]\]            USA                                                                                       Mixed         Prostate cancer              379            5874              1.04    0.91     1.20    rs8050136           No
  Delahanty, 2011 \[[@R10]\]       China                                                                                     East Asian    Endometrial cancer           832            2049              1.07    0.89     1.29    rs9939609           No
  Kaklamani, 2011 \[[@R11]\]       USA                                                                                       Mixed         Breast cancer                302            349               0.992   0.78     1.26    rs9939609           No
                                                                                                                                                                                                         0.975   0.77     1.23                        Yes
                                                                                                                                                                                                         1.408   1.11     1.79    rs1477196           No
                                                                                                                                                                                                         1.447   1.13     1.85                        Yes
  Lurie, 2011 \[[@R12]\]           Australia, USA, Poland, and Canada                                                        European      Endometrial cancer           3561           5167              1.07    0.99     1.14    rs9939609           No
                                                                                                                                                                                                         1.01    0.94     1.08                        Yes
  Pierce, 2011 \[[@R13]\]          Finland, USA, China, France, Germany, Greece, Italy, The Netherlands, Spain, and the UK   European      Pancreatic cancer            1763           1802              1.12    1.02     1.23    rs8050136           No
  Tang, 2011 \[[@R14]\]            USA                                                                                       Mixed         Pancreatic cancer            1053           1130              1.08    0.96     1.22    rs9939609           No
                                                                                                                                                                                                         1.03    0.80     1.30                        Yes
  Brooks, 2012 \[[@R15]\]          USA and Denmark                                                                           European      Breast cancer                643            1271              1.1     0.9      1.3     rs9939609           No
  Hubacek, 2012 \[[@R16]\]         Czech Republic, Hungary, Poland, Romania, Russia, and Slovakia                            European      Colorectal cancer            1005           6827              1.02    0.93     1.13    rs17817449          No
  Kitahara, 2012 \[[@R17]\]        USA                                                                                       European      Thyroid cancer               341            444               0.77    0.62     0.94    rs9939609           No
                                                                                                                                                                                                         0.76    0.61     0.93                        Yes
                                                                                                                                                                                                         1.31    1.07     1.61    s1477196            No
                                                                                                                                                                                                         1.32    1.07     1.61                        Yes
  Kusinska, 2012 \[[@R18]\]        Poland                                                                                    European      Breast cancer                134            357               1.05    0.68     1.61    rs9939609           No
  Lim, 2012 \[[@R19]\]             USA                                                                                       Mixed         Colorectal cancer            2033           9640              1.02    0.93     1.11    rs9939609           No
  Machiela, 2012 \[[@R20]\]        USA and several European countries                                                        European      Prostate cancer              2782           4458              0.93    0.86     1.00    rs9939609           Yes
  Tarabra, 2012 \[[@R21]\]         Italy                                                                                     European      Colorectal cancer            341            311               1.01    0.81     1.25    rs9939609           No
  Akilzhanova, 2013 \[[@R22]\]     Kazakhstan                                                                                European      Breast cancer                315            604               0.96    0.78     1.17    rs1477196           No
                                                                                                                                                                                                         0.96    0.78     1.17                        Yes
  da Cunha, 2013 \[[@R23]\]        Brazil                                                                                    European      Breast cancer                100            148               0.86    0.60     1.25    rs9939609           No
                                                                                                                                                                                                         0.87    0.61     1.26                        Yes
  Garcia-Closas, 2013 \[[@R24]\]   USA and many European countries                                                           European      Breast cancer                10706          76647             1.11    1.07     1.15    rs11075995          No
                                                                                                                                                                        3071           20130             1.16    1.09     1.24                        Yes
  Iles, 2013 \[[@R25]\]            European countries                                                                        European      Melanoma                     13060          60726             1.03    0.97     1.10    rs8050136           No
  Lin, 2013 \[[@R26]\]             Japan                                                                                     East Asian    Pancreatic cancer            360            400               1.33    1.04     1.72    rs9939609           No
                                                                                                                                                                                                         1.41    1.07     1.85                        Yes
  Long, 2013 \[[@R27]\]            USA                                                                                       African       Breast cancer                1113           930               1.21    1.06     1.37    rs17817449          Yes
  Zheng, 2013 \[[@R28]\]           China, Korea, Japan and Thailand                                                          East Asian    Breast cancer                16797          18983             0.92    0.88     0.97    rs17817449          No
  Zhang, 2014 \[[@R29]\]           China                                                                                     East Asian    Breast cancer                2901           2789              1.06    0.98     1.14    rs11075995          No
  Mojaver, 2015 \[[@R30]\]         Iran                                                                                      Middle East   Breast cancer                99             100               0.85    0.51     1.41    rs9939609           No
                                                                                                                                                                                                         1.215   0.683    2.161                       Yes
                                                                                                                                                                                                         1.14    0.64     2.01    rs1477196           No
                                                                                                                                                                                                         0.890   0.464    1.707                       Yes
  Zeng,2015 \[[@R31]\]             China                                                                                     East Asian    Breast cancer                537            537               1.19    0.90     1.57    rs9939609           No
                                                                                                                                                                                                         1.18    0.89     1.56                        Yes
                                                                                                                                                                                                         0.73    0.58     0.93    rs1477196           No
                                                                                                                                                                                                         0.75    0.59     0.96                        Yes
                                                                                                                                                                                                         0.90    0.71     1.15    rs11075995          No
                                                                                                                                                                                                         0.94    0.73     1.20                        Yes
  Zhao, 2016\[[@R32]\]             Several European countries                                                                European      Breast cancer                62328          83817             0.94    0.92     0.95    rs9939609           No

\* All included studies were case-control designed.

Meta-analysis results {#s2_2}
---------------------

Overall, *FTO* rs9939609 SNP was not associated with cancer risk without adjustment for BMI (OR=1.01, 95%CI=0.97-1.05). In the subgroup analysis by race/ethnicity, before adjustment for BMI, there was no any significant associations in European population, East Asian population, Middle East population and mixed population (all *P*\>0.05) (Figure [2](#F2){ref-type="fig"}). After adjustment for BMI, *FTO* rs9939609 SNP risk allele was associated with cancer risk in East Asian population (OR=1.29, 95%CI=1.06-1.57) and African population (OR=1.21, 95%CI=1.06-1.38), but not in European population, Middle East population and Mixed population (all *P*\>0.05) (Figure [3](#F3){ref-type="fig"}). In the subgroup analysis by cancer type, *FTO* rs9939609 SNP risk allele marginally increased risk of endometrial cancer (OR=1.07, 95%CI=1.00-1.14) and pancreatic cancer (OR=1.12, 95%CI=1.04-1.21), while it marginally decreased risk of breast cancer (OR=0.94, 95%CI=0.92-0.96) (Table [2](#T2){ref-type="table"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Overall, there was also no significant association between *FTO* rs9939609 SNP and cancer risk with adjustment for BMI (OR=1.01, 95%CI=0.93-1.10). *FTO* rs9939609 SNP risk allele marginally decreased risk of prostate cancer (OR=0.93, 95%CI=0.88-0.99), while it marginally increased risk of breast cancer (OR=1.12, 95%CI=0.99-1.26) (Table [2](#T2){ref-type="table"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

![Forest plot of the effect of *FTO* rs9939609 on risk of cancer by race/ethnicity without adjustment for body mass index](oncotarget-08-50987-g002){#F2}

![Forest plot of the effect of *FTO* rs9939609 on risk of cancer by race/ethnicity with adjustment for body mass index](oncotarget-08-50987-g003){#F3}

###### Associations between *FTO* variants and cancer risk by cancer type

                           OR     95% CI      *I*^2^ (%)   *P* ~for\ heterogeneity~
  ------------------------ ------ ----------- ------------ --------------------------
  **rs9939609**                                            
   Before BMI adjustment                                   
    All                    1.01   0.97-1.05   65.8         \<0.001
    Endometrial cancer     1.07   1.00-1.14   0            0.985
    Breast cancer          0.94   0.92-0.96   1.8          0.416
    Pancreatic cancer      1.12   1.04-1.21   6.8          0.342
    Colorectal cancer      1.02   0.96-1.09   0            0.996
    Others                 0.98   0.92-1.05   57.4         0.038
   After BMI adjustment                                    
    All                    1.01   0.93-1.10   64.9         0.001
    Breast cancer          1.12   0.99-1.26   14.2         0.324
    Pancreatic cancer      1.20   0.88-1.63   64.7         0.093
    Prostate cancer        0.93   0.88-0.99   0            0.864
    Others                 0.89   0.68-1.18   84.1         0.012
  **rs1477196**                                            
   Before BMI adjustment                                   
    All                    1.07   0.97-1.20   80.1         \<0.001
    Breast cancer          1.00   0.88-1.13   80.2         0.002
    Thyroid cancer         1.31   1.07-1.61   \-           \-
   After BMI adjustment                                    
    All                    1.08   0.97-1.21   79.4         0.001
    Breast cancer          1.00   0.88-1.14   79.1         0.002
    Thyroid cancer         1.32   1.08-1.62   \-           \-
  **rs11075995**                                           
   Before BMI adjustment                                   
    Breast cancer          1.08   1.01-1.15   47.2         0.150
    After BMI adjustment                                   
    Breast cancer          1.08   0.89-1.31   61.2         0.108

There was no significant association between *FTO* rs1477196 SNP and cancer risk without (OR=1.07, 95%CI= 0.97-1.20) or with (OR=1.08, 95%CI=0.97-1.21) adjustment for BMI. However, we found a significant association between *FTO* rs1477196 SNP and risk of thyroid cancer without (OR=1.31, 95%CI=1.07-1.61) or with (OR=1.32, 95%CI=1.08-1.62) adjustment for BMI (Table [2](#T2){ref-type="table"} and [Supplementary Figures 3-4](#SD1){ref-type="supplementary-material"}).

*FTO* rs11075995 SNP risk allele was associated with breast cancer risk without adjustment for BMI (OR=1.08, 95%CI=1.01-1.15) (Table [2](#T2){ref-type="table"} and [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). However, the significant association disappeared after adjustment for BMI (OR=1.08, 95%CI=0.89-1.31) (Table [2](#T2){ref-type="table"} and [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}).

Publication bias {#s2_3}
----------------

There was no publication bias for *FTO* rs9939609, rs1477196 or rs11075995 SNP using Begg\'s test or Egger\'s test (all *P*\>0.05).

DISCUSSION {#s3}
==========

Our updated meta-analysis shows that *FTO* rs9939609 SNP was associated with some types of cancer, such as endometrial cancer, pancreatic cancer and breast cancer without adjustment for BMI, while it was still associated with breast cancer and prostate cancer with adjustment for BMI. In addition, *FTO* rs1477196 SNP was associated with thyroid cancer independently of BMI and *FTO* rs11075995 SNP was associated with breast cancer dependently on BMI.

Several meta-analyses have addressed the association between *FTO* SNP and risk of diabetes, \[[@R36]\] hypertension, \[[@R37]\] cardiovascular disease, \[[@R38]\] polycystic ovary syndrome \[[@R39]\] and mortality \[[@R40]\]. Most of these meta-analyses supported *FTO* SNP was associated with health outcomes independently of adiposity. A meta-analysis of data from 169,551 Caucasian adults showed that the hazards ratio (HR) for the A minor allele of the *FTO* rs9939609 SNP was 1.02 (1.00--1.04, *P*=0.097), but the association disappeared after adjustment for BMI (HR=1.00; 0.98--1.03, *P*=0.662) \[[@R40]\]. These results suggested that *FTO* SNP risk allele increases risk of mortality directly through adiposity pathway.

It seemed that *FTO* rs9939609 SNP played different roles in the development of different cancer, as well as in different populations. Previous studies demonstrated that BMI was associated with risk of common cancer, but its association with some cancer types differed between sexes and different ethnic populations \[[@R41]\]. As *FTO* SNP rs9939609 was strongly associated with BMI, it is not surprising that this variant was associated with some types of cancer but not with other types of cancer.

The FTO protein is highly expressed in hypothalamus, as well as in many other tissues: mesenteric fat, adipose, pancreatic, and liver. It regulates the global metabolic rate, energy expenditure, energy homeostasis, body size and body fat accumulation \[[@R42]\]. *FTO* rs8050136 was reported to preferentially bind to cut-like homeobox (*CUTL*1) in human fibroblast DNA and silencing this transcriptional factor CUTL1 could lead to decreased FTO expression in fibroblasts \[[@R43]\]. In addition, *FTO* SNP was strongly associated with expression of a tumor suppressor/cell cycle-repressing gene, namely retinoblastoma-like 2 \[[@R44]\]. Further studies are necessary to clarify the underlying mechanism between *FTO* SNP and cancer risk.

Our study has several strengths. First, our study included 27 publications consisting of \~130, 000 cases and \~300,000 controls, which had the larger statistical power than three previous meta-analyses \[[@R33]--[@R35]\]. Second, we presented results without and with adjustment for BMI, but the previous three meta-analyses didn't. Third, besides rs9939609 and its proxy SNP (rs8050136 and rs17817449), we also investigated two other SNPs (rs1477196 or rs11075995), which are not in high LD with rs9939609. However, several limitations should be noted. First, the effects of gene-gene/gene-environment interactions were not addressed in this meta-analysis as the included individual studies did not provided us with these data. Second, although the total sample size was large enough, it was still limited for some types of cancer. Thus, the subgroup results with limited statistical power should be interpreted with caution. Third, there was significant heterogeneity between studies for three SNPs and the results should be interpreted cautiously.

In conclusion, our updated meta-analysis supported that *FTO* SNP was associated with some types of cancer, which was mediated by BMI or independent of BMI. Further studies should focus on gene-gene/gene-environment interaction in the development of cancer. Epigenetics and metabonomics should be paid more attention in order to solve how BMI modify the association between *FTO* SNP and cancer risk.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

We searched PubMed and Embase databases for the potentially eligible studies. The following key words were used to search the eligible publications: (fat-mass and obesity-associated gene OR *FTO*) and (polymorphism OR variant OR variation OR genotype) and (cancer OR tumor OR carcinoma). We restricted publication language to English. The reference lists of retrieved articles were also hand-searched. The literature search was updated by July 14, 2016.

Inclusion criteria and data extraction {#s4_2}
--------------------------------------

The included studies met all the following inclusion criteria: (1) investigation of the association of *FTO* rs9939609 SNP (or any proxy SNP (rs8050136, rs17817449), *r*^2^\>0.90) or other SNPs which are not in tight LD with rs9939609 (such as rs1477196 and rs11075995) with cancer risk; (2) use of a case--control or cohort design; and (3) provision of an odds ratio (OR) with 95% confidence interval (CI) with or without adjustment for body mass index (BMI). The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country of origin; (4) race/ethnicity of the study population; (5) number of cases and controls; (6) type of cancer; (7) studied SNP; and (8) whether adjusted for BMI in the logistical regression model. Two authors independently reviewed the articles for compliance with the inclusion/exclusion criteria, resolved disagreements and reached a consistent decision after discussion with the third author.

Statistical analysis {#s4_3}
--------------------

The associations of *FTO* SNPs with cancer risk were estimated by calculating the pooled ORs and 95% CIs under an additive genetic model. The significance of the OR was determined by the Z test (*p*\<0.05 was considered statistically significant). Cochrane\'s Q test was performed to test the between-study heterogeneity \[[@R45], [@R46]\]. *I*^2^ represents the range for degree of heterogeneity. A random-effects (DerSimonian--Laird \[[@R45]\]) or fixed-effects (Mantel--Haenszel \[[@R46]\]) model was used to calculate the pooled OR in the presence (*p*≤0.10 or *I*^2^≥50%) or absence (*p*\>0.10 and *I*^2^\<50%) of heterogeneity, respectively. Publication bias was assessed by Begg\'s test and Egger\'s test \[[@R47]\] (*p*\<0.05 was considered statistically significant). Data were analyzed using STATA version 11.0 (StataCorp LP, College Station, TX, USA).

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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